RxDoctor Payments Data

Alyssa Ferland

Psychiatric/Mental Health · Worcester, MANPI 1023743135

Payments from drug & device makers

$2,724in general payments, 2019–2025

Across 138 payments — averaging $19.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$469
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$384
  • Johnson & Johnson$324
  • Otsuka America Pharmaceutical, Inc.$308
  • Neurocrine Biosciences, Inc.$212
  • Alkermes, Inc.$210
  • plus $816 from 8 others

What the payments were for

  • Food & beverage$2,724100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,724 in reported general payments places this provider in the 90th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

See all psychiatric/mental health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$37,865
Medicare patients
91
Services billed
414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl41$83,704
Abilify MaintenaAripiprazole22$61,740
CaplytaLumateperone Tosylate25$47,959
AuvelityDextromethorphan Hbr/Bupropion18$18,173
Lurasidone Hcl28$9,248
Aripiprazole23$3,570
Buspirone Hcl80$2,278
Clozapine46$1,513
Quetiapine Fumarate66$1,092
Bupropion Hcl SrBupropion Hcl37$1,056
Trazodone Hcl92$1,055
Duloxetine Hcl53$1,012
Bupropion XlBupropion Hcl38$993
Chlorpromazine Hcl12$915
Lamotrigine65$910

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$189$83,70441 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$308$61,74022 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$384$47,95925 claims
Axsome Therapeutics, Inc.Auvelity$69$18,17318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

Other psychiatric/mental health in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →